These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 16862169)
1. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oakes SR; Robertson FG; Kench JG; Gardiner-Garden M; Wand MP; Green JE; Ormandy CJ Oncogene; 2007 Jan; 26(4):543-53. PubMed ID: 16862169 [TBL] [Abstract][Full Text] [Related]
2. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis. Li M; Lewis B; Capuco AV; Laucirica R; Furth PA Oncogene; 2000 Feb; 19(8):1010-9. PubMed ID: 10713684 [TBL] [Abstract][Full Text] [Related]
3. Haploid inactivation of the amplified-in-breast cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor gamma and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice. Zhang H; Kuang SQ; Liao L; Zhou S; Xu J Cancer Res; 2004 Oct; 64(19):7169-77. PubMed ID: 15466215 [TBL] [Abstract][Full Text] [Related]
4. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Forrester E; Chytil A; Bierie B; Aakre M; Gorska AE; Sharif-Afshar AR; Muller WJ; Moses HL Cancer Res; 2005 Mar; 65(6):2296-302. PubMed ID: 15781643 [TBL] [Abstract][Full Text] [Related]
5. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379 [TBL] [Abstract][Full Text] [Related]
6. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Witty JP; Lempka T; Coffey RJ; Matrisian LM Cancer Res; 1995 Apr; 55(7):1401-6. PubMed ID: 7882342 [TBL] [Abstract][Full Text] [Related]
7. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Zhang H; Stephens LC; Kumar R Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771 [TBL] [Abstract][Full Text] [Related]
9. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874 [TBL] [Abstract][Full Text] [Related]
10. Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice. Liu ML; Shibata MA; Von Lintig FC; Wang W; Cassenaer S; Boss GR; Green JE Oncogene; 2001 Apr; 20(16):2044-9. PubMed ID: 11360188 [TBL] [Abstract][Full Text] [Related]
11. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. Wennbo H; Gebre-Medhin M; Gritli-Linde A; Ohlsson C; Isaksson OG; Törnell J J Clin Invest; 1997 Dec; 100(11):2744-51. PubMed ID: 9389738 [TBL] [Abstract][Full Text] [Related]
12. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418 [TBL] [Abstract][Full Text] [Related]
13. Prolactin controls mammary gland development via direct and indirect mechanisms. Brisken C; Kaur S; Chavarria TE; Binart N; Sutherland RL; Weinberg RA; Kelly PA; Ormandy CJ Dev Biol; 1999 Jun; 210(1):96-106. PubMed ID: 10364430 [TBL] [Abstract][Full Text] [Related]
14. Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis. Medina D; Kittrell FS; Hill J; Shepard A; Thordarson G; Brown P Cancer Res; 2005 Apr; 65(8):3493-6. PubMed ID: 15833886 [TBL] [Abstract][Full Text] [Related]
15. Functional mammary gland development and oncogene-induced tumor formation are not affected by the absence of the retinoblastoma gene. Robinson GW; Wagner KU; Hennighausen L Oncogene; 2001 Oct; 20(48):7115-9. PubMed ID: 11704837 [TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis. Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling. Zhang X; Mehta RG; Lantvit DD; Coschigano KT; Kopchick JJ; Green JE; Hedayat S; Christov KT; Ray VH; Unterman TG; Swanson SM Carcinogenesis; 2007 Jan; 28(1):143-50. PubMed ID: 16916863 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of the colony-stimulating factor (CSF-1) and/or its receptor c-fms in mammary glands of transgenic mice results in hyperplasia and tumor formation. Kirma N; Luthra R; Jones J; Liu YG; Nair HB; Mandava U; Tekmal RR Cancer Res; 2004 Jun; 64(12):4162-70. PubMed ID: 15205327 [TBL] [Abstract][Full Text] [Related]
19. Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma. Manhès C; Kayser C; Bertheau P; Kelder B; Kopchick JJ; Kelly PA; Touraine P; Goffin V J Endocrinol; 2006 Aug; 190(2):271-85. PubMed ID: 16899561 [TBL] [Abstract][Full Text] [Related]